Literature DB >> 21553104

A retrospective statistical analysis of high-grade soft tissue sarcomas.

Gregory G Kolovich1, Adam N Wooldridge, Jonathan M Christy, Martha K Crist, Joel L Mayerson, Thomas J Scharschmidt.   

Abstract

Soft-tissue sarcomas have a mortality rate ranging from 40-60% for high-grade lesions. Prior identified risk factors for post-surgical mortality include tumor size, lesion histology, and margin status at resection. A better understanding of prognostic factors is needed to guide patient counseling and treatment. Data were collected from 129 patients surgically treated for high-grade extremity soft tissue sarcomas during 2002-2010. The primary endpoint was death related to high-grade soft tissue sarcoma. Thirteen variables were investigated: age, gender, race, tumor size, margin status, location, estimated blood loss, operative blood transfusions, pre-operative metastatic disease, pre-operative radiation, post-operative radiation, pre-operative chemotherapy, and post-operative chemotherapy. A Cox Survival Analysis model was created to determine the best predictors of survival time. Tumor size and the presence of pre-surgical metastasis were statistically significant predictors of overall survival. Patients with a tumor greater than 8 cm in any cross section had a 3.15 times greater chance of death. Presence of pre-surgical metastasis carried a 3.47 greater chance of death. The remaining variables did not predict patient outcomes in a statistically significant manner. The hazard ratios calculated add new data and can be used to more effectively guide patients in prognosis and treatment regimens.

Entities:  

Mesh:

Year:  2011        PMID: 21553104     DOI: 10.1007/s12032-011-9970-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  43 in total

1.  Do surgical margin and local recurrence influence survival in soft tissue sarcomas?

Authors:  Eduardo N Novais; Bahtiyar Demiralp; Joseph Alderete; Melissa C Larson; Peter S Rose; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

Review 2.  Bone sarcomas: Overview of management, with a focus on surgical treatment considerations.

Authors:  Steven A Lietman; Michael J Joyce
Journal:  Cleve Clin J Med       Date:  2010-03       Impact factor: 2.321

3.  Local recurrence and survival in soft-tissue sarcomas.

Authors:  C P Karakousis; C Proimakis; U Rao; A F Velez; D L Driscoll
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

4.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

5.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

6.  Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

Authors:  J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

7.  Surgical treatment of 297 soft tissue sarcomas of the lower extremity.

Authors:  M H Shiu; E B Castro; S I Hajdu; J G Fortner
Journal:  Ann Surg       Date:  1975-11       Impact factor: 12.969

8.  Localized extremity soft tissue sarcoma: an analysis of factors affecting survival.

Authors:  C Collin; J Godbold; S Hajdu; M Brennan
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

9.  Recurrence-free survival time for surgically treated soft tissue sarcoma patients. Multivariate analysis of five prognostic factors.

Authors:  H W Heise; M H Myers; W O Russell; H D Suit; F M Enzinger; J H Edmonson; J Cohen; R G Martin; W T Miller; S I Hajdu
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

Review 10.  Soft-tissue sarcoma.

Authors:  Nathan F Gilbert; Christopher P Cannon; Patrick P Lin; Valerae O Lewis
Journal:  J Am Acad Orthop Surg       Date:  2009-01       Impact factor: 3.020

View more
  6 in total

1.  One-year mortality in patients with bone and soft tissue sarcomas as an indicator of delay in presentation.

Authors:  R Nandra; N Hwang; G S Matharu; K Reddy; R Grimer
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

2.  Soft tissue sarcoma: adding diffusion-weighted imaging improves MR imaging evaluation of tumor margin infiltration.

Authors:  Ji Hyun Hong; Won-Hee Jee; Chan-Kwon Jung; Joon-Yong Jung; Seung Han Shin; Yang-Guk Chung
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

3.  Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?

Authors:  Jason Klein; Alex Ghasem; Samuel Huntley; Nathan Donaldson; Martin Keisch; Sheila Conway
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

Review 4.  Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.

Authors:  John Charlson
Journal:  Curr Treat Options Oncol       Date:  2018-10-25

5.  What morphological MRI features enable differentiation of low-grade from high-grade soft tissue sarcoma?

Authors:  Sana Boudabbous; Marion Hamard; Essia Saiji; Karel Gorican; Pierre-Alexandre Poletti; Minerva Becker; Angeliki Neroladaki
Journal:  BJR Open       Date:  2022-06-22

6.  Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy.

Authors:  Meena Bedi; David M King; Mikesh Shivakoti; Tao Wang; Eduardo V Zambrano; John Charlson; Donald Hackbarth; John Neilson; Robert Whitfield; Dian Wang
Journal:  Radiat Oncol       Date:  2013-03-14       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.